ArticleCancers2020
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective.Clinical and molecular hepatology · 2023Guideline
- The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt.Internal medicine (Tokyo, Japan) · 2026Article
- Lenvatinib in radioiodine-refractory differentiated thyroid cancer: a real-world institutional analysis.Endocrine journal · 2026Article
- Impact of high relative dose intensity on effectiveness and treatment continuity of IO-TKI therapy in Japanese advanced renal cell carcinoma.Scientific reports · 2026Article
- Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib.Journal of liver cancer · 2026Review
- Endoscopic Innovation Treatment Strategy in Hepatocellular Carcinoma (HCC) Patients Before Immunotherapy: A Case Series Study in Unselected Patients.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.Mediastinum (Hong Kong, China) · 2026Review
- Case Report: Lenvatinib-induced lichenoid drug reaction mimicking disseminated zoster in a patient with metastatic hepatocellular carcinoma.Frontiers in oncology · 2026Article
- Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan.International journal of clinical oncology · 2025Observational
- Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects.Current oncology (Toronto, Ont.) · 2025Review
- Mild Primary Adrenal Insufficiency During Treatment With Lenvatinib and Pembrolizumab: A Report of 3 Patients.JCEM case reports · 2025Article
- Real-World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan.Thoracic cancer · 2025Article
- Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency.Frontiers in endocrinology · 2025Article
- Adverse Events in Targeted Therapy for Unresectable Hepatocellular Carcinoma Predict Clinical Outcomes.Cancers · 2024Article
- Article
- Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study.Cancer medicine · 2024Article
- Relevance of plasma lenvatinib concentrations and endogenous urinary cytochrome P450 3A activity biomarkers in clinical practice.Pharmacology research & perspectives · 2024Article
- Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment.Oncology letters · 2024Article
- Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.Hepatology international · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Hideki IwamotoDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Hiroyuki SuzukiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Shigeo ShimoseDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Takashi NiizekiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Masahito NakanoDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Tomotake ShironoDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Shusuke OkamuraDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Yu NodaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Naoki KamachiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Toru NakamuraDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Atsutaka MasudaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Takahiko SakaueDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Toshimitsu TanakaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Dan NakanoDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Miwa SakaiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Taizo YamaguchiIwamoto Internal Medicine Clinic, Kitakyusyu 802-0832, Japan.
Ryoko KuromatsuDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Hironori KogaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Takuji TorimuraDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Kurume University · JP
Funding
Japan Society for the Promotion of Science 18K15831
Abstract
PubMed holds no abstract for this paper.
Indexed as
adverse eventshepatocellular carcinomalenvatinibmolecular targeted agentsweekends-off
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.